Drug Development

Catalent acquires drug services firm Juniper

by Michael McCoy
July 6, 2018 | APPEARED IN VOLUME 96, ISSUE 28


The drug delivery and development services firm Catalent has agreed to acquire Juniper Pharmaceuticals for $133 million. Juniper’s pharma services division offers drug industry customers solid-state and preclinical formulation screening as well as bioavailability enhancement technologies. Catalent says Juniper’s Nottingham, England, facility will be a European complement to its drug development centers in Somerset, N.J. and San Diego.


This article has been sent to the following recipient:

Leave A Comment

*Required to comment